XERS - Xeris Biopharma Holdings, Inc.
NEXT EARNINGS:
Mar 2, 2026
(in 5 days)
EPS Est: $0.03
|
Rev Est: $86.0M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$13.50
DETAILS
HIGH:
$18.00
LOW:
$9.00
MEDIAN:
$13.50
CONSENSUS:
$13.50
UPSIDE:
102.10%
Market Cap:
1.11B
Volume:
1,035,972
Avg Volume:
1,998,613
52 Week Range:
3.58-10.08
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.93
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
394
IPO Date:
2018-06-21
EPS (TTM):
-0.37
P/E Ratio:
-9.07
Revenue (TTM):
203.07M
Total Assets:
323.06M
Total Debt:
271.45M
Cash & Equiv:
71.62M
Rev Growth (5Y):
136.8%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-12.0%
Debt/Equity:
-9.17
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-06 | $0.00 | $0.01 | -65.0% | $74.4M | $86.0M | -13.5% |
| 2025-08-07 | $-0.01 | $-0.03 | +66.7% | $71.5M | $72.2M | -1.0% |
| 2025-05-08 | $-0.06 | $-0.07 | +14.3% | $60.1M | $57.6M | +4.4% |
| 2025-03-06 | $-0.03 | $-0.08 | +62.5% | $60.1M | $54.9M | +9.5% |
| 2024-11-08 | $-0.06 | $-0.09 | +33.3% | $54.3M | $51.4M | +5.5% |
| 2024-08-08 | $-0.10 | $-0.11 | +9.1% | $48.1M | $45.8M | +4.9% |
| 2024-05-09 | $-0.14 | $-0.12 | -16.7% | $40.6M | $41.8M | -2.8% |
| 2024-03-06 | $-0.10 | $-0.09 | -11.1% | $44.4M | $45.8M | -3.1% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 203.07M | 163.91M | 110.25M | 49.59M | 20.43M | 2.72M | 2.46M | 1.56M | 1.07M |
| Net Income | (54.84M) | (62.26M) | (94.66M) | (122.72M) | (91.14M) | (125.58M) | (60.08M) | (26.55M) | (13.21M) |
| EPS | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 | -3.49 | -4.99 | -13.09 | -7.17 |
| Total Assets | 323.06M | 322.60M | 344.52M | 304.36M | 159.15M | 108.99M | 120.03M | 45.00M | 33.53M |
| Total Debt | 271.45M | 229.19M | 198.06M | 88.07M | 87.02M | 58.30M | 31.89M | 0 | 0 |
| Cash & Equivalents | 71.62M | 67.45M | 121.97M | 67.27M | 37.60M | 19.52M | 45.72M | 42.05M | 32.27M |
| Operating Cash Flow | (36.98M) | (47.02M) | (102.89M) | (102.89M) | (95.53M) | (80.56M) | (56.28M) | (24.66M) | (16.09M) |
| Free Cash Flow | (37.85M) | (49.29M) | (103.42M) | (103.42M) | (96.62M) | (80.94M) | (57.79M) | (25.36M) | (16.12M) |
| FCF per Share | -0.26 | -0.36 | -0.76 | -1.31 | -2.27 | -3.10 | -4.80 | -12.51 | -8.75 |
| Book Value | (29.61M) | (6.78M) | 45.19M | 95.23M | 33.76M | 14.44M | 75.41M | (57.83M) | (31.93M) |
| Cash & ST Investments | 71.62M | 72.45M | 121.97M | 102.43M | 133.79M | 75.55M | 112.63M | 42.05M | 32.27M |
| ROC Equity | N/A | N/A | -2.09 | -1.29 | -2.70 | -8.70 | -0.80 | N/A | N/A |